News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,305 Results
Type
Article (40386)
Company Profile (251)
Press Release (660668)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204614)
Career Advice (2015)
Deals (35505)
Drug Delivery (95)
Drug Development (81347)
Employer Resources (172)
FDA (16279)
Job Trends (14888)
News (346190)
Policy (32744)
Tag
Academia (2583)
Accelerated approval (5)
Adcomms (21)
Allergies (89)
Alliances (49597)
ALS (88)
Alzheimer's disease (1379)
Antibody-drug conjugate (ADC) (124)
Approvals (16282)
Artificial intelligence (258)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11653)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (178)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (278)
Cancer (2258)
Cardiovascular disease (175)
Career advice (1684)
Career pathing (30)
CAR-T (151)
Cell therapy (424)
Cervical cancer (19)
Clinical research (66210)
Collaboration (837)
Compensation (533)
Complete response letters (19)
COVID-19 (2638)
CRISPR (40)
C-suite (241)
Cystic fibrosis (101)
Data (2208)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (271)
Diagnostics (6387)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (122)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (94)
Earnings (86740)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112619)
Executive appointments (722)
FDA (17541)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (750)
Gene editing (105)
Generative AI (19)
Gene therapy (305)
GLP-1 (712)
Government (4445)
Grass and pollen (6)
Guidances (67)
Healthcare (18888)
Huntington's disease (23)
IgA nephropathy (28)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2785)
Inflammatory bowel disease (138)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (313)
IPO (16543)
IRA (40)
Job creations (3644)
Job search strategy (1428)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (17)
Legal (8006)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (305)
MASH (67)
Medical device (13488)
Medtech (13493)
Mergers & acquisitions (19507)
Metabolic disorders (687)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1916)
NextGen: Class of 2025 (6541)
Non-profit (4492)
Now hiring (39)
Obesity (365)
Opinion (204)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (149)
Partnered (21)
Patents (235)
Patient recruitment (112)
Peanut (48)
People (57430)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20618)
Phase II (29147)
Phase III (21741)
Pipeline (1206)
Policy (139)
Postmarket research (2581)
Preclinical (8758)
Press Release (64)
Prostate cancer (107)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (380)
Real estate (5915)
Recruiting (65)
Regulatory (22379)
Reports (46)
Research institute (2335)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (49)
Schizophrenia (69)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (53)
Special edition (14)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3592)
State (2)
Stomach cancer (13)
Supply chain (69)
Tariffs (40)
The Weekly (29)
Vaccines (720)
Venture capitalists (41)
Weight loss (236)
Women's health (35)
Worklife (16)
Date
Today (203)
Last 7 days (901)
Last 30 days (2634)
Last 365 days (32874)
2025 (10734)
2024 (35309)
2023 (40188)
2022 (51288)
2021 (55866)
2020 (54306)
2019 (46684)
2018 (35139)
2017 (32237)
2016 (31582)
2015 (37690)
2014 (31465)
2013 (26478)
2012 (28688)
2011 (29383)
2010 (27446)
Location
Africa (722)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (38091)
Australia (6242)
California (6132)
Canada (2014)
China (524)
Colorado (267)
Connecticut (275)
Delaware (148)
Europe (81955)
Florida (911)
Georgia (206)
Idaho (57)
Illinois (535)
India (25)
Indiana (307)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (898)
Massachusetts (4584)
Michigan (220)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1728)
New Mexico (28)
New York (1747)
North Carolina (987)
North Dakota (8)
Northern California (2682)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1378)
Puerto Rico (12)
Rhode Island (33)
South America (1102)
South Carolina (23)
South Dakota (1)
Southern California (2301)
Tennessee (101)
Texas (906)
United States (23162)
Utah (180)
Virginia (145)
Washington D.C. (61)
Washington State (550)
West Virginia (3)
Wisconsin (55)
701,305 Results for "respiratory motion inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Thoracic Myelopathy Uncovered: Dr. Hooman Melamed’s Breakthrough Motion-Sparing Spine Surgery
April 28, 2025
·
3 min read
Press Releases
Circadia C200 System Gets FDA 510(k) Clearance, Transforming Senior Care With Contactless Heart Rate, Respiratory Rate, Motion, and Bed Exit Monitoring
November 13, 2024
·
3 min read
Press Releases
Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis
March 27, 2025
·
2 min read
Drug Development
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
Vanda Pharmaceuticals Inc. today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness.
May 15, 2024
·
7 min read
Deals
Novanta completes acquisition of Motion Solutions
Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has completed the acquisition of Motion Solutions.
January 2, 2024
·
7 min read
Press Releases
Pneuma Respiratory Advances Inhaled Therapeutics to Improve Respiratory Health
February 17, 2025
·
3 min read
Press Releases
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
April 17, 2025
·
7 min read
First Patient Enrolled in Merit Medical’s MOTION Study
Merit Medical Systems, Inc. (NASDAQ: MMSI) today announced the successful enrollment of the first patient in its multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (GAE) using Embosphere® Microspheres to corticosteroid injections for the treatment of symptomatic knee osteoarthritis (MOTION) study.
January 16, 2024
·
3 min read
Press Releases
ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
April 9, 2025
·
4 min read
Drug Development
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company’s MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 3, 2024
·
10 min read
1 of 70,131
Next
